What happened with BFLY today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Butterfly Network lets clinicians scan different parts of the body with a single handheld probe. Its Butterfly iQ+ and iQ3 devices use its Ultrasound-on-Chip semiconductor technology, with connected software accessed through mobile devices and hospital computers. Healthcare systems, individual providers and veterinarians pay for the equipment and software subscriptions, with support and training also available. Product sales bring in most revenue; software and other services supply the rest. Most revenue comes from U.S. customers, and one customer accounts for a meaningful share of sales.
Butterfly also licenses its semiconductor platform through Butterfly Embedded for development in markets that do not compete with its medical-device business. Its agreement with Midjourney brings in license and co-development payments and provides for milestone payments, chip purchases and revenue sharing if Midjourney commercializes hardware using Butterfly chips.
The business depends on customers adopting its devices and renewing software subscriptions, and on two key suppliers: TSMC makes all wafers for its ultrasound chips, while Benchmark assembles, tests and supplies finished products. Replacing either would take time and could interrupt deliveries. Butterfly may market its medical devices only for uses cleared or approved by the relevant regulators.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Watch privately held Midjourney: Butterfly's ultrasound-chip licensing partnership with it accounts for $63.2 million of its $99.6 million in remaining performance obligations.
GE HealthCare's VScan competes with Butterfly's handheld probes for clinicians' mobile ultrasound purchases. For Butterfly investors, VScan's uptake among clinicians is the relevant contest—not GE HealthCare's broader sales of medical equipment, services and software to hospitals and health systems.
Philips competes with Butterfly for ultrasound purchases by clinicians and health systems, selling both conventional systems and Lumify handheld devices where Butterfly sells probes.
Butterfly's probe sales depend on Benchmark Electronics, which Butterfly pays as its sole contractor to assemble, test and supply finished probes. Watch production and delivery at Benchmark's Thailand facilities: switching manufacturers would bring extra costs and delays.
Pulsenmore overlaps with Butterfly in mobile ultrasound, but its smartphone-connected devices mainly let patients scan themselves at home, while Butterfly sells to healthcare providers. Its ES device sales through Clalit and Sheba for prenatal patients show how that home-scanning market is developing, rather than demand from skilled clinicians.
Butterfly depends on TSMC to manufacture the integrated circuits inside its proprietary ultrasound probe chips, paying it to turn chip designs into semiconductors. Their jointly developed manufacturing process and continuing process improvements are the part of TSMC's work to watch for Butterfly's single-probe, whole-body imaging technology.
Benchmark Electronics earningsBHE
Benchmark Electronics is Butterfly Network’s sole contract manufacturer for finished probes, so its report offers a read on the supply link Butterfly depends on.
Read Benchmark’s manufacturing results alongside any comments about production or delivery problems; use Thailand-specific detail only if the company reports it. Healthy manufacturing results with no reported disruption would ease concern about probe supply, but would not prove that Butterfly’s own orders or output were unaffected. Weaker results or reported delays matter because changing manufacturers would cost Butterfly time and money, making probe delivery risk more pressing.
GE HealthCare Technologies Inc. earningsGEHC
If GE HealthCare reports Vscan sales or adoption, its results will show how directly those handheld devices compete with Butterfly Network for clinicians’ mobile ultrasound purchases.
First look for Vscan-specific disclosure; GE HealthCare’s overall results cannot substitute for it. If Vscan adoption is growing, clinicians are directing more mobile ultrasound purchases to a direct competitor, putting Butterfly’s probe sales in a more contested market. Weak Vscan adoption would ease that competitive pressure, but would not prove that Butterfly itself is selling more.
Butterfly Network, Inc. earningsThis company
Butterfly Network’s report will show whether probe sales and software and other services are growing together, and leaving more gross profit after costs.
Read product revenue, software and other services revenue, and gross profit together. Product revenue reflects sales of probes and other products; software and other services also include partnership licensing, so they are not all subscriptions. If both revenue streams grow and gross profit follows, demand is broadening beyond hardware and the business is keeping more from each sale. If growth relies mainly on products, or partnership-related services rise without better gross profit, the business remains more dependent on hardware or project revenue, making the improvement less broad-based.
